Kelly Y. Chun, Monique Bastidas, Lythou Yeo, Susie Magpantay, Judah Scott, M. Zikry, Wayne Galdamez
{"title":"S17 使用 Labcorp 阿达木单抗检测试剂盒检测生物仿制药(AMJEVITA™,阿达木单抗-atto)的药物浓度和抗药抗体,对其进行治疗药物监测","authors":"Kelly Y. Chun, Monique Bastidas, Lythou Yeo, Susie Magpantay, Judah Scott, M. Zikry, Wayne Galdamez","doi":"10.14309/01.ajg.0000995804.85093.96","DOIUrl":null,"url":null,"abstract":"Background: There are limited studies assessing the impact of pediatric-onset in fl ammatory bowel disease (IBD) on infant and pregnancy outcomes. Low birth weight and preterm birth are known pregnancy complications in IBD patients with active disease. Therefore, this study sought to evaluate pregnancy outcomes in patients with pediatric-onset versus adult-onset Crohn ’ s disease (CD), particularly with regard to intrauterine growth and prematurity delivery. Methods: In this single center, retrospective comparative cohort study, patients with pediatric-onset (diagnosed , 18 years old) and adult-onset CD (diagnosed $ 18 years old) who had documented prenatal care between 2012-2023 were identi fi ed. Patients were excluded for following at outside institutions for primary IBD care. We compared co-primary outcomes (gestational age and size), and secondary outcomes (assisted reproduction usage, mode of delivery, and neonatal intensive care unit (NICU) stay), between the two groups. Data was obtained from an electronic medical record via natural language processing and con fi rmed with manual veri fi cation. Categorical variables were analyzed using chi-squared test or Fisher exact test when appropriate; continuous variables were assessed with t-test if normally distributed. Statistical signi fi cance was determined by p value , 0.05. Results: A total of 208 infants were delivered, 119 to pediatric-onset CD and eighty-nine to adult-onset CD mothers. There was no signi fi cant di ff erence with regard to race between the groups. The mother ’ s age at delivery was signi fi cantly lower in pediatric-onset CD patients (median [IQR]: 30.2 [26.3, 34.5] vs 32.5 [29.8, 35.3] years, p 5 0.0006). There was a numerically","PeriodicalId":188050,"journal":{"name":"The American Journal of Gastroenterology","volume":"61 ","pages":"S5 - S6"},"PeriodicalIF":0.0000,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"S17 Therapeutic Drug Monitoring of the Biosimilar (AMJEVITA™, Adalimumab-atto) Using Labcorp Adalimumab Assay for Drug Level and Anti-Drug Antibodies\",\"authors\":\"Kelly Y. Chun, Monique Bastidas, Lythou Yeo, Susie Magpantay, Judah Scott, M. Zikry, Wayne Galdamez\",\"doi\":\"10.14309/01.ajg.0000995804.85093.96\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: There are limited studies assessing the impact of pediatric-onset in fl ammatory bowel disease (IBD) on infant and pregnancy outcomes. Low birth weight and preterm birth are known pregnancy complications in IBD patients with active disease. Therefore, this study sought to evaluate pregnancy outcomes in patients with pediatric-onset versus adult-onset Crohn ’ s disease (CD), particularly with regard to intrauterine growth and prematurity delivery. Methods: In this single center, retrospective comparative cohort study, patients with pediatric-onset (diagnosed , 18 years old) and adult-onset CD (diagnosed $ 18 years old) who had documented prenatal care between 2012-2023 were identi fi ed. Patients were excluded for following at outside institutions for primary IBD care. We compared co-primary outcomes (gestational age and size), and secondary outcomes (assisted reproduction usage, mode of delivery, and neonatal intensive care unit (NICU) stay), between the two groups. Data was obtained from an electronic medical record via natural language processing and con fi rmed with manual veri fi cation. Categorical variables were analyzed using chi-squared test or Fisher exact test when appropriate; continuous variables were assessed with t-test if normally distributed. Statistical signi fi cance was determined by p value , 0.05. Results: A total of 208 infants were delivered, 119 to pediatric-onset CD and eighty-nine to adult-onset CD mothers. There was no signi fi cant di ff erence with regard to race between the groups. The mother ’ s age at delivery was signi fi cantly lower in pediatric-onset CD patients (median [IQR]: 30.2 [26.3, 34.5] vs 32.5 [29.8, 35.3] years, p 5 0.0006). There was a numerically\",\"PeriodicalId\":188050,\"journal\":{\"name\":\"The American Journal of Gastroenterology\",\"volume\":\"61 \",\"pages\":\"S5 - S6\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The American Journal of Gastroenterology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.14309/01.ajg.0000995804.85093.96\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The American Journal of Gastroenterology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14309/01.ajg.0000995804.85093.96","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
背景:评估小儿罹患炎症性肠病(IBD)对婴儿和妊娠结局的影响的研究很有限。低出生体重和早产是活动性 IBD 患者已知的妊娠并发症。因此,本研究试图评估儿科发病与成人发病的克罗恩病(CD)患者的妊娠结局,尤其是在宫内发育和早产方面。研究方法在这项单中心、回顾性比较队列研究中,对 2012-2023 年间有产前护理记录的儿科发病型(诊断年龄在 18 岁以下)和成人发病型 CD 患者(诊断年龄在 18 岁以上)进行了识别。排除了在外部机构接受初级 IBD 治疗的患者。我们比较了两组患者的共同主要结局(胎龄和胎儿大小)和次要结局(辅助生殖使用、分娩方式和新生儿重症监护室(NICU)住院时间)。数据通过自然语言处理从电子病历中获取,并经过人工验证。分类变量采用卡方检验(chi-squared test)或费舍尔精确检验(Fisher exact test)进行分析;连续变量采用 t 检验(如果是正态分布)进行评估。统计意义以 p 值大于 0.05 为准。结果共接生了 208 名婴儿,其中 119 名婴儿的母亲是儿童发病型 CD 患者,89 名婴儿的母亲是成人发病型 CD 患者。两组之间没有明显的种族差异。儿科发病的 CD 患者母亲的分娩年龄明显较低(中位数 [IQR]: 30.2 [26.3, 34.5] vs 32.5 [29.8, 35.3] 岁,P 5 0.0006)。在数字上
S17 Therapeutic Drug Monitoring of the Biosimilar (AMJEVITA™, Adalimumab-atto) Using Labcorp Adalimumab Assay for Drug Level and Anti-Drug Antibodies
Background: There are limited studies assessing the impact of pediatric-onset in fl ammatory bowel disease (IBD) on infant and pregnancy outcomes. Low birth weight and preterm birth are known pregnancy complications in IBD patients with active disease. Therefore, this study sought to evaluate pregnancy outcomes in patients with pediatric-onset versus adult-onset Crohn ’ s disease (CD), particularly with regard to intrauterine growth and prematurity delivery. Methods: In this single center, retrospective comparative cohort study, patients with pediatric-onset (diagnosed , 18 years old) and adult-onset CD (diagnosed $ 18 years old) who had documented prenatal care between 2012-2023 were identi fi ed. Patients were excluded for following at outside institutions for primary IBD care. We compared co-primary outcomes (gestational age and size), and secondary outcomes (assisted reproduction usage, mode of delivery, and neonatal intensive care unit (NICU) stay), between the two groups. Data was obtained from an electronic medical record via natural language processing and con fi rmed with manual veri fi cation. Categorical variables were analyzed using chi-squared test or Fisher exact test when appropriate; continuous variables were assessed with t-test if normally distributed. Statistical signi fi cance was determined by p value , 0.05. Results: A total of 208 infants were delivered, 119 to pediatric-onset CD and eighty-nine to adult-onset CD mothers. There was no signi fi cant di ff erence with regard to race between the groups. The mother ’ s age at delivery was signi fi cantly lower in pediatric-onset CD patients (median [IQR]: 30.2 [26.3, 34.5] vs 32.5 [29.8, 35.3] years, p 5 0.0006). There was a numerically